TIDMNCYT
RNS Number : 7059C
Novacyt S.A.
24 January 2018
NOVACYT REVENUES FULL YEAR 2017
Delivers record revenue growth of 35%
China sales exceed expectations
Successfully completed dual-listing on AIM
Paris, France and Cambridge, UK - 24 January 2018 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, is pleased to announce its unaudited revenues
for the full year ended 31 December 2017.
In 2017, Novacyt continued to deliver against its three
strategic pillars of organic, acquisition and R&D led growth.
During the year, Novacyt specifically focused on organic growth
following the May 2016 acquisition and subsequent integration of
Primerdesign and, as a result, reports record sales growth across
the entire business in 2017. Novacyt is expected to continue to
make significant progress in 2018 towards becoming a profitable and
cash generative global clinical diagnostics company.
Financial highlights
-- Consolidated Group sales increased 35%(1) to EUR15.0m
(GBP13.1m) compared with EUR11.1m (GBP9.1m) in 2016
-- Sales growth represented 43%(1) at constant exchange rates
(CER), equating to EUR15.9m in sales in
2017
-- All parts of the Group achieved double digit sales growth at CER
-- Successfully completed a dual-listing on the Alternative
Investment Market (AIM) of the London Stock Exchange in October
2017, raising EUR9.7m (GBP8.8m) before expenses
-- Novacyt ended the year with EUR4.3m (GBP3.8m) in cash
following the payment of a deferred Primerdesign milestone,
deleveraging of the balance sheet and confirmed it will make no
further drawdowns against the Yorkville convertible bond
facility
Divisional revenues
-- Primerdesign sales increased to EUR6.1m (GBP5.3m) compared
with pro forma sales of EUR5.1m (GBP4.2m) in the prior year,
representing 27% growth on a pro forma CER basis
-- Primerdesign revenue growth was partly driven by new sales in
China, which was the fastest growing region, and increased from
EUR4,900 (GBP4,000) to EUR0.97m (GBP0.85m)
-- NOVAprep(R) sales increased 36% to EUR2.2m, which is the
fastest annual sales growth by this division so far reported by the
Group
-- NOVAprep(R) sales in Asia Pacific grew by 184% in 2017,
continuing to be the division's fastest growing region
-- Lab21 revenues grew 8% (16% CER) to EUR6.7m (GBP5.8m) driven by strong core product growth
Operational highlights
-- In October 2017, Novacyt successfully completed a pioneering
dual-listing on AIM, adding to the Company's existing Euronext
Growth Paris listing. This important step in Novacyt's development
provides access to a deeper potential pool of capital and raises
the Group's international and capital markets profiles
-- As reported on 4 September 2017, Primerdesign secured
significant new business in China, which was expected to be
delivered by the end of the year. Actual sales of EUR0.97m
(GBP0.85m) were recognised in the year, exceeding management's
initial expectations
-- Novacyt recruited a total of 36 additional employees during
the year across the business, in particular adding commercial and
manufacturing capacity to help facilitate accelerated revenue
growth
-- Continued to invest in senior commercial hires with the key
appointments of Phil Sefton, Ruth Powell and Paul Eros as Managing
Directors of the three business divisions
-- Completed the build and relocation to a new 15,000 square
feet manufacturing site in Camberley on target in September 2017 to
support the planned growth of the Group
Graham Mullis, Group CEO of Novacyt, commented:
"I am delighted to report record organic sales growth across the
Group in 2017 in a year where we successfully completed a
pioneering dual-listing on AIM. This listing will enable Novacyt to
further raise its international profile and accelerate our
ambitious organic and inorganic growth plans.
"The new senior management hires made during the year provides
the foundations and the leadership to further drive performance. Of
note, the sales growth, particularly achieved in China, from both
Primerdesign and NOVAprep(R) products has been pleasing as it
exceeded our expectations. It also validates our investment in the
region and we plan to build upon this success in 2018 by investing
further, whilst working closely with our new distribution
partners.
"With continued organic sales growth and strong gross margins,
we are aiming to move into profitable trading during 2018 to
strengthen the basis for future growth. I look forward to updating
shareholders of our progress in due course."
Current trading and outlook
During 2018, the Group will continue to build on the organic
sales progress made in 2017 and will evaluate the potential for
further accretive acquisitions. It also expects to report further
progress in the development of the product pipeline for
Primerdesign. Management therefore believes that Novacyt is on
track to continue to deliver against all three of its strategic
growth pillars.
Key dates for the company's results disclosure include:
-- Full year 2017 results - 26 April 2018
-- AGM - TBC
-- Half-year 2018 revenues - 26 July 2018
-- Half-year 2018 results - 19 September 2018
Inside Information
This announcement contains inside information. The person
responsible for arranging for the release of this announcement on
behalf of the Company is Anthony Dyer.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAPrep(R), and molecular platform, genesig(R), Novacyt
is able to provide an extensive range of oncology and infectious
disease diagnostic products across an extensive international
distributor network. The Group has diversified sales from
diagnostic reagents used in oncology, microbiology, haematology and
serology markets, and its global customers and partners include
major corporates.
For more information please refer to the website:
www.novacyt.com
[1] The acquisition of Primerdesign was completed in May 2016
and the total Group consolidated revenues include Primerdesign from
1 May 2016
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSEFFIDFASEDF
(END) Dow Jones Newswires
January 24, 2018 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024